United States Patent 8,962,028: Halobetasol Topical Lotion Claims, Scope, Exclusivity and Patent Landscape
U.S. Patent No. 8,962,028 protects a storage-stable, oil-in-water halobetasol lotion defined by three elements: a halobetasol active ingredient, a specific emollient-humectant carrier containing diisopropyl adipate, and stringent stability performance. The patent also covers narrower formulation ratios, droplet-size distributions, packaging configurations, treatment methods, hydration outcomes, and a manufacturing process.
The broadest practical risk is claim 1. A competing product must avoid at least one required formulation component, ratio, stability limitation, or other claim element to reduce literal infringement exposure. Claims 14 and 16 are materially narrower but potentially important for products using the disclosed 0.05% halobetasol composition.
What does U.S. Patent 8,962,028 protect?
The patent is a formulation and manufacturing patent, not a basic halobetasol compound patent. Its independent claims cover:
| Claim |
Subject matter |
Commercial relevance |
| 1 |
Storage-stable topical halobetasol lotion |
Primary composition claim |
| 19 |
Treatment of corticosteroid-responsive dermatoses using the lotion |
Method-of-use claim |
| 29 |
Preparation of the lotion by heated aqueous and oil-phase emulsification |
Manufacturing-process claim |
The central formulation requires:
- Halobetasol or a pharmaceutically acceptable salt, ester, or solvate.
- A pharmaceutically acceptable carrier.
- One or more fatty alcohols or alkoxylated fatty alcohols.
- One or more polyol humectants.
- Diisopropyl adipate.
- A fatty alcohol or alkoxylated fatty alcohol to humectant to diisopropyl adipate ratio of 30-60:30-60:5-15 by weight.
- Specified stability performance at 40°C, 30°C, and 25°C.
The claim is therefore a combination claim. The presence of halobetasol alone does not create infringement. The carrier architecture and stability limitations are essential.
How broad is claim 1?
Claim 1 is broad in ingredient identity but narrow in formulation architecture and performance.
Active ingredient scope
The term “halobetasol material” includes halobetasol and its pharmaceutically acceptable salts, esters, and solvates. Claim 6 expressly identifies halobetasol propionate, the commercially relevant corticosteroid form.
The claim does not require a particular halobetasol concentration. That limitation is supplied in narrower claims 14 and 16. A formulation containing a concentration other than 0.05% may still fall within claim 1 if it satisfies the carrier, ratio, and stability limitations.
Carrier scope
The required carrier contains three functional groups:
- Fatty alcohols or alkoxylated fatty alcohols.
- Polyol humectants.
- Diisopropyl adipate.
Claim 2 identifies fatty alcohols including lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, and octyldodecanol. Claim 3 identifies corresponding ethoxylated alcohols. Claim 4 lists glycerin, propylene glycol, butylene glycol, dipropylene glycol, pentylene glycol, hexylene glycol, and polyethylene glycol as polyol humectants.
The dependent claims do not appear to limit claim 1 to only those listed examples. They provide narrower embodiments. A formulation using a different fatty alcohol or humectant may remain within claim 1 if the broader claim language covers it and the other limitations are satisfied.
Ratio limitation
Claim 1 requires the following weight ratio:
| Component group |
Claim 1 range |
| Fatty alcohols and alkoxylated fatty alcohols |
30-60 |
| Polyol humectants |
30-60 |
| Diisopropyl adipate |
5-15 |
The ratio is not a ratio of the total formulation. It is a relative ratio among the three identified component groups. This distinction is material. A product could contain only 3% diisopropyl adipate in the total lotion and still satisfy the claim if the three component groups fall within the required relative proportions.
Claims 8 through 10 narrow the ratio:
| Claim |
Ratio |
| 8 |
39-48:39-50:10-15 |
| 9 |
44-46:40-43:11-13 |
| 10 |
46:42:12 |
Claim 10 is a fixed-ratio embodiment and is easier to test analytically than the broader ranges.
What stability performance is required?
Claim 1 requires all three stability outcomes:
| Storage condition |
Required result |
| Six months at 40°C |
More than 98.5% of the manufactured halobetasol remains |
| 26 months at 30°C |
Less than 1% degradation |
| 30 months at 25°C |
Less than 3% degradation |
Claim 5 narrows the first condition to less than 1.5% degradation, while retaining the two longer-term limitations.
These are performance limitations, not merely formulation descriptions. A product containing the same ingredients and ratio may avoid the claim if it does not meet the specified stability thresholds. The patent owner, however, would need reliable analytical evidence showing the applicable assay method, degradation products, sampling protocol, batch history, and storage conditions.
The claim’s language creates a potential interpretation issue: the first limitation measures remaining active as a percentage of the amount at manufacture, while the later limitations measure degradation as a percentage of the original amount. A technical dispute could arise over assay correction, potency versus total halobetasol-related material, and whether degradation includes conversion to specified degradants or any loss from the initial assay value.
What formulations are protected by claims 14 and 16?
Claims 14 and 16 describe commercially recognizable 0.05% halobetasol lotion embodiments.
Claim 14 formulation
Claim 14 requires the following approximate composition:
| Ingredient |
Amount |
| Halobetasol material |
0.02-0.10% |
| Diisopropyl adipate |
1-5% |
| Octyldodecanol |
5-15% |
| Polyethylene glycol 1000 cetyl ether |
0.50-2% |
| Surfactant |
0.50-2% |
| Cetyl alcohol |
1-3% |
| Stearyl alcohol |
1-2% |
| Preservative |
0.05-0.2% |
| Propylene glycol |
5-15% |
| Glycerin |
1-5% |
| pH adjustment agent |
pH approximately 5-6.5 |
| Water |
Quantity sufficient |
Claim 15 adds a viscosity control agent at 0.1-0.5% by weight.
Claim 16 formulation
Claim 16 is more specific:
| Ingredient |
Amount |
| Halobetasol material |
0.05% |
| Diisopropyl adipate |
3.5% |
| Octyldodecanol |
10% |
| Polyethylene glycol 1000 cetyl ether |
1% |
| Surfactant |
1% |
| Cetyl alcohol |
2% |
| Stearyl alcohol |
0.66% |
| Preservative |
0.15% |
| Propylene glycol |
10% |
| Glycerin |
2.5% |
| pH adjustment agent |
pH approximately 5-6.5 |
| Water |
Quantity sufficient |
Claim 17 specifies propyl paraben, butyl paraben, or their combination. Claim 18 adds a viscosity control agent at 0.25% by weight.
A competing 0.05% halobetasol lotion using octyldodecanol, cetyl alcohol, stearyl alcohol, polyethylene glycol 1000 cetyl ether, propylene glycol, glycerin, and diisopropyl adipate would warrant a detailed claim chart against claims 1, 9, 10, 16, 17, and 18.
Does the patent require an oil-in-water emulsion?
Claims 11 through 13 require an oil-in-water emulsion with specified droplet sizes:
| Claim |
Mean droplet size |
Distribution |
| 11 |
0.1-50 microns |
0.1-50 microns |
| 12 |
1-10 microns |
0.15-15 microns |
| 13 |
1.5-7 microns |
0.175-10 microns |
These limitations do not apply to claim 1 unless the claim is read through a dependent claim. A product can therefore face claim 1 exposure without satisfying the narrower droplet-size limitations in claims 11-13.
For litigation, particle-size measurement methodology would matter. Relevant variables include dilution, instrument type, refractive-index assumptions, sampling location, aggregate treatment, and whether the reported mean is volume-, number-, or intensity-weighted.
What method-of-use protection does the patent provide?
Claim 19 covers topical administration of the claimed lotion to treat corticosteroid-responsive dermatoses. Claims 20-24 add packaging and patient-use instructions.
The method claims cover:
- Use in a patient with a corticosteroid-responsive dermatosis.
- Packaging in a suitable storage and delivery container.
- Containers made of ferrous alloy, aluminum, glass, plastic, or combinations.
- Protective coatings.
- At least two separate compartments.
- Cleansing the treatment area with a surfactant-containing composition.
Claims 25 through 28 add functional treatment outcomes. These include reduced transepidermal water loss compared with a cream formulation and improved skin hydration measured by skin conductance or capacitance, including measurements at two or four hours after treatment.
The practical value of these claims depends on the approved label, promotional instructions, physician prescribing behavior, and evidence of direct or induced infringement. A generic label that instructs use for the same corticosteroid-responsive dermatoses could create method-of-use exposure even if the generic formulation attempts to avoid narrower composition claims.
What manufacturing process is protected by claim 29?
Claim 29 covers a process with the following sequence:
- Prepare an aqueous phase containing a first portion of the ingredients.
- Maintain the aqueous phase at 45-70°C.
- Prepare an oil phase containing a second portion of the ingredients.
- Add the oil phase to the aqueous phase while stirring at about 45-70°C.
- Cool the emulsion to about 25-35°C.
- Adjust pH to 5.0-6.5.
The process claim is narrower than a general claim to manufacturing a halobetasol lotion. A manufacturer using a cold-process method, a different phase-addition sequence, continuous emulsification, or a substantially different pH-adjustment step may reduce literal infringement risk.
Process evidence can include batch records, master manufacturing records, standard operating procedures, equipment settings, temperature logs, and deviations. Trade-secret manufacturing information may make this claim difficult to enforce without discovery or testing.
How does this patent compare with other halobetasol patent categories?
| Patent category |
Typical protected subject matter |
Relationship to 8,962,028 |
| Active-ingredient patent |
Halobetasol or halobetasol propionate itself |
Separate and generally older |
| Classic dosage-form patent |
Ointment, cream, or solution |
May overlap clinically but not necessarily compositionally |
| Lotion formulation patent |
Vehicle, stability, emulsion, excipients |
Closest category |
| Foam formulation patent |
Aerosol foam, propellant system, foam stability |
Usually technically distinct |
| Method-of-use patent |
Psoriasis, plaque psoriasis, eczema, or dermatoses |
May overlap claims 19-28 |
| Manufacturing patent |
Mixing, emulsification, temperature, pH |
Claim 29 category |
| Packaging patent |
Container, dispenser, barrier, compartment |
Claims 20-23 provide limited packaging coverage |
The patent should not be treated as a blanket monopoly over every halobetasol topical product. Its most relevant competitive target is a lotion using the same or similar emollient-humectant system and making comparable stability claims.
What is the Orange Book status of U.S. Patent 8,962,028?
Orange Book listing is product- and NDA-specific. A patent may be listed for one approved halobetasol product and not for another product containing the same active ingredient. The patent number alone does not establish current listing status, delisting status, or whether the patent is tied to a particular approved labeling limitation.
For regulatory diligence, the relevant records are:
- FDA Orange Book patent and exclusivity data.
- The approved NDA record for the reference halobetasol lotion.
- FDA patent-listing submissions and updates.
- The patent’s current USPTO status.
- Any terminal disclaimer or patent-term adjustment.
- Any court decision affecting enforceability or claim construction.
The patent does not create biosimilar risk. Halobetasol is a chemically synthesized small molecule, so an applicant would generally use an ANDA pathway rather than a 351(k) biosimilar pathway. The relevant challenge mechanism would be a Paragraph IV certification if the patent is listed against the applicable reference product.
When does the patent lose exclusivity?
The claims supplied do not provide the earliest effective filing date, priority chain, patent-term adjustment, patent-term extension, or terminal disclaimer. Those records control the expiration date. The grant date alone cannot establish the statutory expiration date.
For a generic launch analysis, the controlling sequence is:
| Event |
Required analysis |
| Patent filing and priority |
Establish the 20-year term baseline |
| Continuity data |
Identify provisional, continuation, divisional, or international priority |
| Patent-term adjustment |
Add USPTO examination delay, if applicable |
| Patent-term extension |
Determine whether FDA regulatory review generated extension |
| Terminal disclaimer |
Determine whether expiration is tied to another patent |
| Orange Book listing |
Determine whether the patent triggers Paragraph IV notice and a potential 30-month stay |
| Litigation |
Determine whether claims remain enforceable and whether an injunction or settlement applies |
A patent-expiration date should not be inferred from the February 2015 grant date.
What Paragraph IV and generic-entry risks exist?
A generic applicant could challenge the patent by asserting that:
- The proposed lotion lacks one required carrier component.
- The component ratio falls outside the claimed range.
- The product does not meet the stability limitations.
- The patent claims are anticipated or obvious in view of earlier halobetasol lotions and emulsion technology.
- The stability limitations are indefinite or not adequately enabled.
- The method claims are not infringed by the proposed label.
- The process claim is avoided by a different manufacturing sequence.
The patent owner could respond that:
- The ratio limitation captures the accused composition.
- Stability is an inherent property of the accused formulation.
- The formulation’s excipient combination provides an unexpected stability result.
- The generic label induces use for the claimed dermatoses.
- Manufacturing records demonstrate performance of the claimed process.
A Paragraph IV dispute would center on claim construction, analytical testing, prior-art formulation disclosures, and the relationship between formulation composition and stability.
How strong is the patent estate?
The estate appears strongest against a near-copy formulation. Risk increases when a competitor uses:
- Halobetasol propionate at approximately 0.05%.
- Diisopropyl adipate.
- Octyldodecanol.
- Cetyl and stearyl alcohols.
- Polyethylene glycol 1000 cetyl ether.
- Propylene glycol and glycerin.
- Similar pH and oil-in-water emulsion characteristics.
- Comparable long-term stability.
Risk is lower for:
- Halobetasol foam products.
- Ointments and creams with materially different carriers.
- Lotions that omit diisopropyl adipate.
- Products outside the ratio ranges.
- Formulations with different emulsion structures.
- Products manufactured without the claimed heated phase-addition sequence.
The principal vulnerability is that claim 1 combines composition limitations with measurable stability results. That structure can provide strong protection against technically similar products, but it creates invalidity and non-infringement opportunities if the prior art discloses comparable stable halobetasol vehicles or if the stability results cannot be reproduced under the claimed conditions.
Key Takeaways
- U.S. Patent 8,962,028 is a halobetasol topical lotion formulation patent.
- Claim 1 requires halobetasol, fatty alcohol or alkoxylated fatty alcohol, polyol humectant, diisopropyl adipate, a defined ratio, and specified stability performance.
- Claims 14 and 16 target detailed 0.05% halobetasol lotion compositions.
- Claims 11-13 add oil-in-water emulsion and droplet-size limitations.
- Claims 19-28 cover treatment, packaging, cleansing instructions, and hydration-related outcomes.
- Claim 29 covers a heated aqueous/oil-phase emulsification process followed by cooling and pH adjustment.
- The patent does not cover every halobetasol topical product.
- The principal generic risk concerns a composition that closely reproduces the disclosed vehicle and stability profile.
- Orange Book listing, expiration, terminal disclaimer, and litigation status require product-specific FDA and USPTO records rather than the claim text alone.
- Halobetasol is a small molecule, so biosimilar analysis is not applicable; ANDA and Paragraph IV analysis is the relevant framework.
FAQs About U.S. Patent 8,962,028
Does the patent cover halobetasol foam?
Not inherently. A foam product would need to satisfy the composition limitations of an asserted claim. A foam using a different vehicle and propellant system would normally require a separate infringement analysis.
Does a halobetasol lotion infringe if it contains diisopropyl adipate?
Not automatically. The product must also satisfy the required fatty alcohol or alkoxylated fatty alcohol component, polyol humectant, ratio, halobetasol limitation, and stability requirements.
Can a generic avoid the patent by using a different preservative?
Potentially, but changing the preservative alone may not avoid claim 1. Claims 1 and 14 do not depend on one specific preservative, while claim 17 expressly identifies paraben embodiments.
Are claims 25 through 28 treatment-efficacy claims?
Yes. They recite outcomes involving transepidermal water loss and skin hydration measured by conductance or capacitance. Their enforceability depends on claim construction, evidence of the claimed result, and the accused label or use.
Is claim 29 a product-by-process claim?
No. Claim 29 is a process claim directed to preparing the lotion through specified aqueous-phase and oil-phase processing, temperature, cooling, and pH-adjustment steps. A materially different process may avoid literal infringement even if it produces a similar lotion.
References
-
United States Patent No. 8,962,028, “Topical lotion compositions comprising halobetasol.” United States Patent and Trademark Office, 2015.
-
United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure: Patent term and patent term adjustment provisions. https://www.uspto.gov
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
